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| INTRODUCTION
Animal models are critical to study the biology of venous thrombosis (VT). The electrolytic inferior vena cava model (EIM) was developed to simulate VT in the clinical scenario of a non-occlusive thrombus.
By applying a small constant current to a copper wire inserted into the inferior vena cava (IVC), free radicals are released which activate endothelial cells and initiate the thrombotic process in the constant presence of blood flow. These conditions mimic the clinical scenario of a non-occlusive thrombus ( Figure 1 ). [1] [2] [3] This method produces a thrombus that is highly consistent in size. The EIM has been used in the United States and beyond to study VT in both anti-thrombotic and prothrombotic conditions, demonstrating the flexibility of the model. 4, 5 Since the initial development of the EIM in 2010, several changing circumstances have driven a need for an update on the model. First, the originally described stimulator equipment was expensive and has since been discontinued. Second, the dependence of thrombus size on current and time were assumed, but had not previously been demonstrated. Third, increasing interest in targeting the fibrinolytic system for treatment of VT and the results of the ATTRACT trial emphasize a need for basic science evidence on the fibrinolytic system of thrombi in the presence of blood flow. 6, 7 The EIM provides a favorable environment for such therapeutic targets due to the sustained blood flow access to the thrombus. However, the fibrinolytic system had not previously been investigated in the EIM. In this communication, we addressed all three of these important updates; we developed an equipment alternative to the previously described system, investigated the current and time dependency of thrombus size, and characterized the fibrinolytic system in the EIM.
| MATERIALS AND METHODS

| Mice and EIM surgical procedure
All experiments were performed at the University of Michigan with approval from the University of Michigan's Institutional Animal Care and Use Committee (IACUC) and conducted in accordance with The Guide for the Care and Use of Laboratory Animals. 8 Male C57BL/6 mice aged 10-12 weeks were anesthetized with 2% isoflurane, placed in dorsal recumbency, and a midline laparotomy was performed. The IVC was exposed, any lateral branches were ligated using 7-0 Prolene suture (Ethicon, Inc., Somerville, NJ), and back branches remained patent. A 30-gauge silver coated copper wire (KY-30-1-GRN, Electrospec, Dover, NJ, USA) with exposed copper wire at the end was attached to a 25-gauge needle and inserted into the IVC and positioned against the anterior wall (anode). Another needle was implanted subcutaneously at the proximal end of the laparotomy incision, completing the circuit (cathode). A detailed video demonstrating the surgical technique is available.
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A constant current of 250 μA was applied for 15 minutes for standard procedures. 3 To investigate the current and time dependency of the EIM, either the current or time was modified to 100 μA or 7.5 minutes, respectively. The current was supplied by either the previously described Grass S48 square wave stimulator and constant current unit (Grass Technologies, Astro-Med, Inc., West Warwick, RI), or by the voltage-to-current converter, described below ( Figure 2 ).
Essentials
• Three key updates are provided on the electrolytic inferior vena cava model (EIM).
• The originally described stimulator equipment has been discontinued; we developed an alternative.
• The fibrinolytic system and the current and time dependency of the EIM was characterized.
• EIM allows the investigation of the fibrinolytic system, critical for endovascular therapies. 
| EIM equipment
EIM was performed either with the previously described discontinued stimulator and constant current unit, or with a voltage to current converter (VIC), as pictured in Figure 2 where I L is the current applied to the load, typically 250 μA, R1 is the resistor used, V IN is the positive and negative input voltage, and G is the gain. A gain resistor (R G ) is not needed for this application, so the gain (G) remains at 1. The circuit was powered by a DC power supply (Agilent E3630A, KeySight Technologies, Santa Rosa, CA, USA). Prior to surgery, a sample load resistor (e.g. 100 Ω) was connected to the circuit and a multimeter was connected in series to fine tune the supplied voltage to deliver 250 μA (or desired current) to the load.
| Validation and characterization
In vivo validation of the VIC was performed by comparing thrombus weights at days 2, 6, and 11-post thrombus induction against thrombi produced using the stimulator and constant current unit. Following validation, the vein wall was isolated for qRT-PCR analysis, and 500 μL of blood was collected for circulating plasminogen activator inhibitor (PAI)-1 activity assay. EIM was performed in a separate group of mice for immunohistochemistry at the same time points.
Additionally, to investigate the current and time dependency of the EIM, thrombus was induced in three groups: standard, 250 μA for 15 min; reduced current, 100 μA for 15 min; and reduced time, 250 μA for 7.5 min. Thrombus volume was followed over time using MRI, described below.
| Thrombus weight
At the time of euthanasia, the IVC and the associated thrombus were removed and weighed for wet thrombus weight. The IVC was separated from the aorta and surrounding tissue, and a segment from just below the left renal vein to the iliac bifurcation was removed for weighing. The lymph nodes were removed from the IVC prior to weighing. After determining thrombus weight, the vein wall was separated from the thrombus for subsequent assessment by qRT-PCR.
The EIM was developed using a square wave stimulator and constant current unit (C, Grass Technologies), both of which are discontinued. Construction of a standard voltage-to-current converter (VIC)-circuit diagram shown in A and constructed circuit with standard DC power supply shown in B-provide a cost-effective alternative.
The VIC was validated on the benchtop and then in vivo by thrombus weights at days 2, 6, and 11 to the Grass S48 system (n = 5 per group, mean ± SEM, D). DC, direct current; EIM, electrolytic inferior vena cava model; NS, not statistically significant; VIC, voltage to current converter 
| Thrombus volume assessment by MRI (in vivo)
The current and time dependency of the EIM was investigated in three groups of mice (standard, reduced current, or reduced time).
Thrombus size was monitored in vivo by MRI at days 1, 2, 4, 6, 9, 11, and 14 following thrombus induction. Mice were anesthetized using 2% isoflurane and imaged supine on a preclinical 7 Tesla MRI scanner.
Respiration was monitored with a respiratory pillow (SA Instruments, Inc., NY, USA), and a PID controller was used to maintain the ani- Thrombus volume was assessed by summing thrombus area in each axial slice (MRVision, Winchester, MA, USA).
| Quantitative real-time polymerase chain reaction
Ribonucleic acid (RNA) was isolated from the IVC wall by homog- Francisco, CA, USA), as previously described. 9, 10 Gene expression was normalized to β-actin (mouse β-actin: PPM02945B) levels for each specimen.
| Immunohistochemistry
Harvested IVC samples containing thrombus were formalin fixed for 2 hours, dehydrated in alcohol, paraffin embedded, and cut into 5 μm longitudinal sections. Nonspecific sites were blocked with normal serum, and sections were incubated with primary antibodies to Plasminogen (1:500, Genetex, Inc.; Catalog number GTX102877, Irvine, CA, USA) A species-specific ABC peroxidase kit (Vector Laboratories Inc., Burlingame, CA, USA) was used according to the manufacturer's instructions for the corresponding secondary antibody and subsequent steps. Color development was performed with diaminobenzidine (DAB). Mosaic images were created via light microscopy (Nikon, Tokyo, Japan) under 40x magnification and quantification of percent positive staining was performed as previously described. 
| PAI-1 activity assay
500 μL of blood was collected by cardiocentesis at harvest using a syringe with 0.05 mL of sodium citrate, and active and total PAI-1 was determined as previously described. 12 In brief, to measure active murine PAI-1 concentrations in plasma samples, human u-PA 
| Statistical analysis
All statistical analyses were completed using GraphPad Prism 7
(GraphPad Software, San Diego, CA, USA). Comparison of thrombus weight between the VIC and Grass S48 was performed using an un- Data was reported as mean ± standard error of the mean (SEM).
| RESULTS
| Voltage-to-current circuit provides costeffective system for performing EIM
We constructed a voltage-to-current converter (VIC) powered by a common DC power supply to offer an equipment alternative to perform the EIM. The development of the VIC provided an added benefit of a significant cost reduction (Table 1 ). In vivo validation of the VIC was performed by comparing thrombus size by wet weight at days 2, 6, and 11 post thrombus induction to thrombi produced using the Grass S48. Thrombus weights were not significantly different between the VIC and Grass S48 at any of the time points studied (Figure 2 ).
| Thrombus size in EIM is both current and time dependent
The dependence of thrombus size on the supplied current and dura- Importantly, thrombus size within each group was highly consistent between mice (coefficient of variation at day 2: controls 11%, reduced current 20%, reduced time 19%).
| The fibrinolytic system is suppressed in acute VT
The fibrinolytic system was investigated in the EIM at days 2, 6, and 11. Qualitatively, positive immunostaining for plasminogen was initially found along the perimeter day 2, with distribution throughout the thrombus at days 6 and 11. Maximum staining was measured at day 6 ( Figure 4 ). Active circulating PAI-1 was significantly increased compared to true controls at days 2 and 11, with peak concentration at day 2 post thrombus induction (day 2: 2764 ± 120 pg/mL, day 11: 1775 ± 292 pg/mL vs. controls: 1063 ± 140 pg/mL, P < .05) ( Figure 5 ). Interestingly, active circulating PAI-1 at day 6 was not different from true controls, indicating a dynamic process of thrombus burden with changing thrombus composition. PAI-1 expression in the IVC wall paralleled active circulating PAI-1 expression ( Figure 5 ). Vein wall PAI-1 expression peaked at day 2, with a down-regulation trend of t-PA and u-PA at the same time point (P = NS). The opposite PAI-1 to t-PA and u-PA relationship was observed at day 11 ( Figure 5 ). 5 This equipment also can be expensive, amounting to several thousands of dollars (Table 1) . Thus, the high cost and discontinuation of the originally described equipment warranted an update to improve accessibility and characterization of the EIM. not provide a range sufficiently low for this application. We chose to implement an operational amplifier constant current source for cost effectiveness, which we powered with a common DC power supply that many labs will have readily available. The VIC was validated on the bench using a multimeter and in vivo by comparing thrombus weight at days 2, 6, and 11, yielding results that were not statistically different from the stimulator and constant current unit. Thus, the model may be implemented at costs comparable to other murine models which only require a surgical scope and anesthesia machine.
| DISCUSSION
Induction of thrombosis in EIM is
Recently, a Japanese group presented a modification to the original EIM description to study a pro-thrombotic phenotype. 5 Typically, maximum thrombus burden is observed at day 2 with a thrombus-to-lumen ratio of 3:1 making this method very suitable to study "thrombus re- Plasminogen, the inactive precursor of the enzyme plasmin which degrades fibrin, is activated by t-PA and u-PA. Interestingly, the immunohistochemistry for plasminogen showed higher total concentrations at day 6, with plasminogen arranged from the thrombus perimeter (day 2) towards the center of the thrombus over time.
This centripetal integration suggests that blood flow access to the thrombus may play an important role in the fibrinolytic process.
Understanding plasminogen dynamics may provide basic science insights that could lead to a better understanding of therapeutic efficacy at different stages of VT.
PAI-1, one of the key inhibitors of t-PA and u-PA, was measured by gene expression in the vein wall and in its active circulating form.
Total circulating PAI-1 correlated with PAI-1 gene expression in the vein wall, and interestingly, the peak of PAI-1 was observed at day 2, coinciding with the decreased expression of t-PA and u-PA. Taken together, this information supports that there is an impairment of the fibrinolytic system activity at day 2 (acute VT) favoring the development of a thrombus. This is aligned with previous work demonstrating that PAI-1 levels peaked at day 2 in the total IVC ligation model, which is considered a blood stasis model. 12 The impairment of the fibrinolytic system during acute VT suggests that VT is not only attributable to coagulation processes, but also a decrease in the fibrinolytic system, regardless of blood flow conditions. This insight not only improves our knowledge of the model but also increases our understanding of VT and is aligned with previous human VT publications. In conclusion, we have demonstrated that the EIM can be performed using a VIC with the added benefit of reduced cost.
Thrombus size in the EIM is both current and time dependent.
We characterized the dynamics of thrombus resolution in reduced current and time of application experiments, further confirming the flexibility of this model to study both anti-thrombotic and prothrombotic conditions. Regardless of the current and time of application used, this model generates thrombi that are highly consistent in size, as was demonstrated previously with thrombus weight and ultrasound, 2 and now by MRI. Additionally, the EIM can be used to investigate the fibrinolytic system under flow conditions. The functionality of the fibrinolytic system increases over time as t-PA and u-PA are up-regulated and plasminogen disseminates throughout the thrombus, providing insights for improving future therapeutic approaches. Hence, the EIM provides a cost-effective, flexible pre-clinical tool for studying the fibrinolytic system in venous thrombosis. 
